Showing 8631-8640 of 9889 results for "".
- April is Rosacea Awareness Monthhttps://practicaldermatology.com/news/20140401-april_is_rosacea_awareness_month/2459281/April is Rosacea Awareness Month and the National Rosacea Society encourages physicians and patients to raise awareness of the disease and its impact on affected individuals. This red-face disorder affects more than 16 million Americans between the ages of 30 and 60. It covers the spectru
- ZO Medical Products Launches in the Middle Easthttps://practicaldermatology.com/news/20140331-zo_medical_products_launches_in_the_middle_east/2459288/ZO Skin Health and Cellogique launched ZO products at the Dubai World Dermatology & Laser Conference Exhibition. Dr. Zein Obagi, board certified dermatologist, developed this product with hopes of representing his skin health principles. “These products empowe
- Joseph R. Williams Becomes Vice President of Global Marketing for Caliber Imaging & Diagnosticshttps://practicaldermatology.com/news/20140326-joseph_r_williams_becomes_vice_president_of_global_marketing_for_caliber_imaging__diagnostics/2459292/Caliber Imaging & Diagnostics named Joseph R. Williams Vice President of Global Marketing. Williams past experience led him to this new position. Previously, he was Director of Market Development at AxsunTechnologies/Volcano Corporation, Senior Director of Global Marketing-Neurosurgery Di
- Merz Aesthetics To Launch New Physician Loyalty Programhttps://practicaldermatology.com/news/20140326-merz_aesthetics_to_launch_new_physician_loyalty_program_my_merz_select/2459293/Merz Aesthetics, a division of Merz North America, announced the upcoming launch of its completely new physician loyalty program, My Merz Select, which will go live on April 1, 2014. My Merz Select is a simple, transparent pro
- Galderma Announces Positive Results of Phase 3 Trials of Investigational Ivermectin 1% Targeting Papulopustular Rosaceahttps://practicaldermatology.com/news/20140325-galderma_announces_positive_results_of_phase_3_trials_of_investigational_ivermectin_1_targeting_papulopustular_rosacea/2459295/Galderma Laboratories, L.P. today announced the results of two pivotal phase 3 trials of ivermectin 1%, an investigational drug being evaluated for the treatment of papulopustular (inflammatory) rosacea. The data were presented at a Late-Breaking session of the 72nd annual meeting of the American Ac
- ADAM Names June McKernan “Practice Manager Of The Year”https://practicaldermatology.com/news/20140323-adam_names_june_mckernan_practice_manager_of_the_year/2459299/The Association of Dermatology Administrators and Managers (ADAM) named June McKernan, Administrator, of Patient Preferred Dermatology of Los Alamitos, CA, the recipient of the organization's inaugural Practice Manager of the Year award. She w
- FDA Approves Novartis Drug Xolair for Chronic Idiopathic Urticariahttps://practicaldermatology.com/news/20140321-fda_approves_novartis_drug_xolair_for_chronic_idiopathic_urticaria/2459302/The FDA approved Xolair (Novartis, omalizumab) for the treatment of chronic idiopathic urticaria (CIU) for patients 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy. Xolair is not used to treat other forms of urticaria (
- Novan Announces Positive Phase 2 Results for Novel Acne Treatmenthttps://practicaldermatology.com/news/20140321-novan_announces_positive_phase_2_results_for_novel_acne_treatment/2459303/Novan Therapeutics announced today positive Phase 2 study results of its topical SB204 drug candidate for the treatment of acne vulgaris. Acne is a skin disease that affects more than fifty million people in the United States. The Phas
- Launch of TrueLipids® Made with Zemea® Propanediolhttps://practicaldermatology.com/news/20140320-launch_of_truelipids_made_with_zemea_propanediol/2459307/Cheryl Lee, MD, Sensitive Skin Care, is soon launching its patent-pending line, TrueLipids® therapeutic products. TrueLipids, now made with Zemea® is designed to repair disrupted skin barriers and promote lipid production, while being cosmetically friendly to the skin. This new li
- FDA approves Impavido to treat tropical disease leishmaniasishttps://practicaldermatology.com/news/20140320-fda_approves_impavido_to_treat_tropical_disease_leishmaniasis/2459308/The US Food and Drug Administration approved Impavido (miltefosine) to treat a tropical disease called leishmaniasis. Leishmaniasis is a disease caused by Leishmania, a parasite which is transmitted to humans through sand fly bites. The disease occurs primarily in people who live in the tropics and